TheraRadar
← Back
Data updated: Jul 17, 2026

MACLEODS PHARMA

Pharma
Respiratory

MACLEODS PHARMA is a pharmaceutical company focused on Respiratory.

-
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

MACLEODS PHARMA's Key Drugs

MACLEODS PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MACLEODS PHARMA's Recent FDA Approvals

New NDA/BLA approvals for MACLEODS PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MACLEODS PHARMA's Therapeutic Areas

MACLEODS PHARMA's approved drugs and pipeline span 1 therapeutic area, led by Respiratory. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 100%
0 drugs Phase 3: 1

MACLEODS PHARMA's Top Competitors

MACLEODS PHARMA's closest competitors by therapeutic-area and drug-target overlap include Novartis, Merck, and GSK. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Novartis big-pharma
Respiratory
Merck big-pharma
Respiratory
GSK big-pharma
Respiratory
Bayer big-pharma
Respiratory
B BRAUN specialty
Respiratory

MACLEODS PHARMA Pipeline Snapshot

MACLEODS PHARMA has 1 active clinical program from ClinicalTrials.gov — 1 Phase 3, 0 Phase 2 and 0 Phase 1.

1
Phase 3
0
Phase 2
0
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling